Jonathan W. Ayers - May 24, 2021 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Director
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan W. Ayers
Stock symbol
IDXX
Transactions as of
May 24, 2021
Transactions value $
-$4,700,335
Form type
4
Date filed
5/26/2021, 05:30 PM
Previous filing
May 24, 2021
Next filing
Jun 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Options Exercise $398K +5K +0.76% $79.54* 659K May 24, 2021 Direct
transaction IDXX Common Stock Sale -$2.73M -5K -0.76% $546.98 654K May 24, 2021 Direct F1
transaction IDXX Common Stock Options Exercise $398K +5K +0.76% $79.54* 659K May 25, 2021 Direct
transaction IDXX Common Stock Sale -$2.65M -4.8K -0.73% $552.12 654K May 25, 2021 Direct F2
transaction IDXX Common Stock Sale -$111K -200 -0.03% $553.37 654K May 25, 2021 Direct
holding IDXX Common Stock 10K May 24, 2021 by Ayers Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -5K -3.7% 130K May 24, 2021 Common Stock 5K $79.54 Direct F3, F4
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -5K -3.85% 125K May 25, 2021 Common Stock 5K $79.54 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average price of the shares sold ranging from a low of $546.545 to a high of $547.27 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2 Represents the weighted average price of the shares sold ranging from a low of $552.00 to a high of $552.675 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3 Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F4 Not applicable.